Adherence to HIV Treatment as Prevention and Preexposure Prophylaxis



Presently, among the estimated near 15 million people living with HIV (PLWH) worldwide in need of antiretroviral therapy (ART), only 54 % have access to ART and, among those with access, some 40 % are unable to achieve high levels of adherence. For over a decade, reasons for ART nonadherence and strategies to promote adequate adherence have been under evaluation, generating numerous models of ART adherence and a host of intervention approaches evaluated in diverse populations. This chapter reviews this literature as well as recent guidelines for the promotion of engagement in HIV care and ART adherence, with special emphasis on application to treatment as prevention (TasP), which relies on high enough rates of ART access and adherence to prevent onward HIV transmission through durably suppressed viral load. Similarly, this chapter also draws out the behavioral pathways underlying the use of preexposure prophylaxis (PrEP) – ARV (antiretroviral) medications for use among HIV-negative persons. Potential strategies for support extrapolated from available evidence gathered to date are identified, and notes of caution provided.


Viral Suppression Community Advisory Board Adherence Support Electronic Drug Monitoring Oral PrEP 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Kobin AB, Sheth NU. Levels of adherence required for virologic suppression among newer antiretroviral medications. Ann Pharmacother. 2011;45(3):372–9. Epub 2011/03/10.PubMedCrossRefGoogle Scholar
  2. 2.
    Foundation KF. The Global HIV/AIDS Epidemic. Fact Sheet. December 2012.Google Scholar
  3. 3.
    Cohen M. Prevention of HIV-1 infection 2013: glimmers of hope. J Int AIDS Soc. 2012;15 Suppl 4:18066. Epub 2012/12/12.Google Scholar
  4. 4.
    Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505. Epub 2011/07/20.PubMedCrossRefGoogle Scholar
  5. 5.
    Cohen MS, Dye C, Fraser C, Miller WC, Powers KA, Williams BG. HIV treatment as prevention: debate and commentary–will early infection compromise treatment-as-prevention strategies? PLoS Med. 2012;9(7):e1001232. Epub 2012/07/18.PubMedCrossRefGoogle Scholar
  6. 6.
    Ortego C, Huedo-Medina TB, Llorca J, Sevilla L, Santos P, Rodriguez E, et al. Adherence to highly active antiretroviral therapy (HAART): a meta-analysis. AIDS Behav. 2011;15(7):1381–96. Epub 2011/04/07.PubMedCrossRefGoogle Scholar
  7. 7.
    Munro S, Lewin S, Swart T, Volmink J. A review of health behaviour theories: how useful are these for developing interventions to promote long-term medication adherence for TB and HIV/AIDS? BMC public health. 2007;7:104. Epub 2007/06/15.PubMedCrossRefGoogle Scholar
  8. 8.
    Amico KR, Harman JJ, Johnson BT. Efficacy of antiretroviral therapy adherence interventions: a research synthesis of trials, 1996–2004. J Acquir Immune Defic Syndr. 2006;41(3):285–97. Epub 2006/03/17.PubMedCrossRefGoogle Scholar
  9. 9.
    Bruin M de, Viechtbauer W, Schaalma HP, Kok G, Abraham C, Hospers HJ. Standard care impact on effects of highly active antiretroviral therapy adherence interventions: A meta-analysis of randomized controlled trials. Arch Intern Med. 2010;170(3):240–50. Epub 2010/02/10.PubMedCrossRefGoogle Scholar
  10. 10.
    Simoni JM, Pearson CR, Pantalone DW, Marks G, Crepaz N. Efficacy of interventions in improving highly active antiretroviral therapy adherence and HIV-1 RNA viral load. A meta-analytic review of randomized controlled trials. J Acquir Immune Defic Syndr. 2006;43 Suppl 1:S23–35. Epub 2006/11/30.PubMedCrossRefGoogle Scholar
  11. 11.
    Thompson MA, Mugavero MJ, Amico KR, Cargill VA, Chang LW, Gross R, et al. Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an International Association of Physicians in AIDS Care panel. Ann Intern Med. 2012;156(11):817–33. Epub 2012/03/07.PubMedCrossRefGoogle Scholar
  12. 12.
    Vernazza P, Hirschel B, Bernasconi E, Flepp M. Les personnes seropositives ne souffrant d’aucune autre MST et suivant un traitement antiretroviral efficace ne transmettent pas le VIH 2 voie sexualle. Bulletin des médecins suisses. 2008;89(5):5.Google Scholar
  13. 13.
    WHO. Programmatic update: Antiretroviral treatment as prevention (TasP) of HIV and TB. WHO/HIV/201212June 2012.Google Scholar
  14. 14.
    Eaton JW, Johnson LF, Salomon JA, Barnighausen T, Bendavid E, Bershteyn A, et al. HIV treatment as prevention: systematic comparison of mathematical models of the potential impact of antiretroviral therapy on HIV incidence in South Africa. PLoS Med. 2012;9(7):e1001245. Epub 2012/07/18.PubMedCrossRefGoogle Scholar
  15. 15.
    Kilmarx PH, Mutasa-Apollo T. Patching a leaky pipe: the cascade of HIV care. Curr opin HIV AIDS. 2013;8(1):59–64. Epub 2012/12/06.PubMedGoogle Scholar
  16. 16.
    El-Sadr WM, Holmes CB, Mugyenyi P, Thirumurthy H, Ellerbrock T, Ferris R, et al. Scale-up of HIV treatment through PEPFAR: a historic public health achievement. J Acquir Immune Defic Syndr. 2012;60 Suppl 3:S96–104. Epub 2012/09/14.PubMedCrossRefGoogle Scholar
  17. 17.
    Mehta M, Semitala F, Lynen L, Colebunders R. Antiretroviral treatment in low-resource settings: what has changed in the last 10 years and what needs to change in the coming years? Expert Rev Anti Infect Ther. 2012;10(11):1287–96. Epub 2012/12/18.PubMedCrossRefGoogle Scholar
  18. 18.
    Dombrowski JC, Harrington RD, Golden MR. Evidence for the long-term stability of HIV transmission-associated sexual behavior after HIV diagnosis. Sex Transm Dis. 2013;40(1):41–5. Epub 2012/12/21.PubMedCrossRefGoogle Scholar
  19. 19.
    Goodreau SM, Carnegie NB, Vittinghoff E, Lama JR, Sanchez J, Grinsztejn B, et al. What drives the US and Peruvian HIV epidemics in men who have sex with men (MSM)? PloS one. 2012;7(11):e50522. Epub 2012/12/05.PubMedCrossRefGoogle Scholar
  20. 20.
    Ganguli I, Bassett IV, Dong KL, Walensky RP. Home testing for HIV infection in resource-limited settings. Curr HIV/AIDS Rep. 2009;6(4):217–23. Epub 2009/10/24.PubMedCrossRefGoogle Scholar
  21. 21.
    Carballo-Dieguez A, Frasca T, Dolezal C, Balan I. Will gay and bisexually active men at high risk of infection use over-the-counter rapid HIV tests to screen sexual partners? J Sex Res. 2012;49(4):379–87. Epub 2012/02/02.PubMedCrossRefGoogle Scholar
  22. 22.
    Alemnji G, Nkengasong JN, Parekh BS. HIV testing in developing countries: what is required? Indian J Med Res. 2011;134(6):779–86. Epub 2012/02/09.PubMedCrossRefGoogle Scholar
  23. 23.
    Chow EP, Wilson DP, Zhang L. The rate of HIV testing is increasing among men who have sex with men in China. HIV medicine. 2012;13(5):255–63. Epub 2012/01/19.PubMedCrossRefGoogle Scholar
  24. 24.
    Fonner VA, Denison J, Kennedy CE, O’Reilly K, Sweat M. Voluntary counseling and testing (VCT) for changing HIV-related risk behavior 2 developing countries. Cochrane Database Syst Rev. 2012;9:CD001224. Epub 2012/09/14.PubMedGoogle Scholar
  25. 25.
    Hermans L, Wensing A, Hoepelman A, Dutihl J, Mudrikova T. Delayed HIV testing in internal medicine clinics—a missed opportunity. The Netherlands J Med. 2012;70(2):69–73. Epub 2012/03/16.Google Scholar
  26. 26.
    Kaai S, Bullock S, Burchell AN, Major C. Factors that affect HIV testing and counseling services among heterosexuals in Canada and the United Kingdom: an integrated review. Patient edu couns. 2012;88(1):4–15. Epub 2011/12/27.CrossRefGoogle Scholar
  27. 27.
    Owen SM. Testing for acute HIV infection: implications for treatment as prevention. Curr opin HIV and AIDS. 2012;7(2):125–30. Epub 2012/02/09.CrossRefGoogle Scholar
  28. 28.
    Thornton AC, Delpech V, Kall MM, Nardone A. HIV testing in community settings in resource-rich countries: a systematic review of the evidence. HIV medicine. 2012;13(7):416–26. Epub 2012/03/15.PubMedCrossRefGoogle Scholar
  29. 29.
    Tripathy S, Pereira M, Tripathy SP. HIV testing in India. Clini lab med. 2012;32(2):175–91. Epub 2012/06/26.CrossRefGoogle Scholar
  30. 30.
    Altice FL, Friedland GH. The era of adherence to HIV therapy. Ann Intern Med. 1998;129(6):503–5. Epub 1998/09/12.PubMedCrossRefGoogle Scholar
  31. 31.
    Blaschke TF, Osterberg L, Vrijens B, Urquhart J. Adherence to medications: insights arising from studies on the unreliable link between prescribed and actual drug dosing histories. Ann rev of pharmacol and toxicol. 2012;52:275–301. Epub 2011/09/29.CrossRefGoogle Scholar
  32. 32.
    Thompson MA, Mugavero MJ, Amico KR, Cargill VA, Chang LW, Gross R, et al. Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an International Association of Physicians in AIDS Care panel. Ann Intern Med. 2012;156(11):817–33, W-284, W-5, W-6, W-7, W-8, W-9, W-90, W-91, W-92, W-93, W-94. Epub 2012/03/07.PubMedCrossRefGoogle Scholar
  33. 33.
    Ammassari A, Lorenzini P, Mussini C, Cozzi-Lepri A, Baldelli F, Gori A, et al. Impact of antiretroviral dosing frequency and daily pill burden on virological success rates in patients of the ICoNA cohort starting their first ART. J Int AIDS Soc. 2012;15(6):18233. Epub 2012/12/14.Google Scholar
  34. 34.
    Bae JW, Guyer W, Grimm K, Altice FL. Medication persistence in the treatment of HIV infection: a review of the literature and implications for future clinical care and research. AIDS. 2011;25(3):279–90. Epub 2011/01/18.PubMedCrossRefGoogle Scholar
  35. 35.
    Osterberg LG, Urquhart J, Blaschke TF. Understanding forgiveness: minding and mining the gaps between pharmacokinetics and therapeutics. Clin Pharmacol Ther. 2010;88(4):457–9. Epub 2010/09/22.PubMedCrossRefGoogle Scholar
  36. 36.
    Bassett IV, Wang B, Chetty S, Mazibuko M, Bearnot B, Giddy J, et al. Loss to care and death before antiretroviral therapy in Durban, South Africa. J Acquir Immune Defic Syndr. 2009;51(2):135–9. Epub 2009/06/09.PubMedCrossRefGoogle Scholar
  37. 37.
    Fleishman JA, Yehia BR, Moore RD, Korthuis PT, Gebo KA. Establishment, retention, and loss to follow-up in outpatient HIV care. J Acquir Immune Defic Syndr. 2012;60(3):249–59. Epub 2012/04/26.PubMedCrossRefGoogle Scholar
  38. 38.
    Ma Y, Zhao D, Yu L, Bulterys M, Robinson ML, Zhao Y, et al. Predictors of virologic failure in HIV-1-infected adults receiving first-line antiretroviral therapy in 8 provinces in China. Clin Infect Dis. 2010;50(2):264–71. Epub 2009/12/19.PubMedCrossRefGoogle Scholar
  39. 39.
    Sayles JN, Rurangirwa J, Kim M, Kinsler J, Oruga R, Janson M. Operationalizing treatment as prevention in Los Angeles County: antiretroviral therapy use and factors associated with unsuppressed viral load in the Ryan White system of care. AIDS Patient Care STDS. 2012;26(8):463–70. Epub 2012/07/11.PubMedCrossRefGoogle Scholar
  40. 40.
    Yehia BR, Fleishman JA, Metlay JP, Moore RD, Gebo KA. Sustained viral suppression in HIV-infected patients receiving antiretroviral therapy. JAMA. 2012;308(4):339–42. Epub 2012/07/24.PubMedCrossRefGoogle Scholar
  41. 41.
    Fox MP, Cutsem GV, Giddy J, Maskew M, Keiser O, Prozesky H, et al. Rates and predictors of failure of first-line antiretroviral therapy and switch to second-line ART in South Africa. J Acquir Immune Defic Syndr. 2012;60(4):428–37. Epub 2012/03/22.PubMedCrossRefGoogle Scholar
  42. 42.
    Simoni JM, Yard SS, Huh D. Prospective prediction of viral suppression and immune response nine months after ART initiation in Seattle, WA. AIDS care. 2013;25(2):181–5. Epub 2012/05/30.PubMedCrossRefGoogle Scholar
  43. 43.
    Colfax GN. Beliefs about viral load and the risk of HIV transmission and associated sexual risk behavior among San Francisco men who have sex with men. XIV International AIDS Conference; Barcelona, Spain2002.Google Scholar
  44. 44.
    Lafeuillade A. Eliminating the HIV reservoir. Curr HIV/AIDS Rep. 2012;9(2):121–31. Epub 2012/03/15.PubMedCrossRefGoogle Scholar
  45. 45.
    Fisher JD, Amico KR, Fisher WA, Harman JJ. The information-motivation-behavioral skills model of antiretroviral adherence 2 its applications. Curr HIV/AIDS Rep. 2008;5(4):193–203. Epub 2008/10/08.PubMedCrossRefGoogle Scholar
  46. 46.
    Fisher JD, Fisher WA, Amico KR, Harman JJ. An information-motivation-behavioral skills model of adherence 2 antiretroviral therapy. Health Psychol. 2006;25(4):462–73. Epub 2006/07/19.PubMedCrossRefGoogle Scholar
  47. 47.
    Tarakeshwar N, Srikrishnan AK, Johnson S, Vasu C, Solomon S, Merson M, et al. A social cognitive model of health for HIV-positive adults receiving care in India. AIDS Behav. 2007;11(3):491–504. Epub 2006/10/10.PubMedCrossRefGoogle Scholar
  48. 48.
    Safren SA, Gonzalez J, Soroudi N. Coping with chronic illness: a cognitive-behavioral therapy approach for adherence and depression: therapist guide (treatments that work). Oxford:Oxford University Press; 2008.Google Scholar
  49. 49.
    El-Sadr WM. HPTN065 TLC-Plus: A study to evaluate the feasibility of an enhanced test, link to care, plus treat approach for HIV prevention in the United States (Protocol v2.0). HIV Prevention Trials Network. 2010.Google Scholar
  50. 50.
    Andersen RM. Revisiting the behavioral model and access to medical care: does it matter? J Health Soc Behav. 1995;36(1):1–10. Epub 1995/03/01.PubMedCrossRefGoogle Scholar
  51. 51.
    Mugavero MJ. Improving engagement in HIV care: what can we do? Top HIV Med. 2008;16(5):156–61. Epub 2008/12/25.PubMedGoogle Scholar
  52. 52.
    Amico K. A situated-Information Motivation Behavioral Skills Model of Care Initiation and Maintenance (sIMB-CIM): an IMB model based approach to understanding and intervening in engagement in care for chronic medical conditions. J Health Psychol. 2011;16(7):1071–81. Epub 2011/04/05.CrossRefGoogle Scholar
  53. 53.
    Smith LR, Fisher JD, Cunningham CO, Amico KR. Understanding the behavioral determinants of retention in HIV care: a qualitative evaluation of a situated information, motivation, behavioral skills model of care initiation and maintenance. AIDS Patient Care STDS. 2012;26(6):344–55. Epub 2012/05/23.PubMedCrossRefGoogle Scholar
  54. 54.
    Bartholomew LK, Parcel GS, Kok G. Intervention mapping: a process for developing theory- and evidence-based health education programs. Health Educ Behav. 1998;25(5):545–63. Epub 1998/10/13.PubMedCrossRefGoogle Scholar
  55. 55.
    Johnson BT, Carey MP, Chaudoir SR, Reid AE. Sexual risk reduction for persons living with HIV: research synthesis of randomized controlled trials, 1993–2004. J Acquir Immune Defic Syndr. 2006;41(5):642–50. Epub 2006/05/03.PubMedCrossRefGoogle Scholar
  56. 56.
    Amico KR, Orrell C. Antiretroviral therapy adherence support: recommendations and future directions. J Int Assoc Provid AIDS Care. 2013;12(2):128–37. Epub 2013/01/22.PubMedGoogle Scholar
  57. 57.
    Amico KR, Orrell C. ART Adherence Support: Recommendations and Future Directions. J Int Assoc Provid AIDS Care. 2013;in press.Google Scholar
  58. 58.
    Simoni JM, Amico KR, Pearson CR, Malow R. Strategies for promoting adherence to antiretroviral therapy: a review of the literature. Curr infect dis rep. 2008;10(6):515–21. Epub 2008/10/24.PubMedCrossRefGoogle Scholar
  59. 59.
    Simoni JM, Amico KR, Smith L, Nelson K. Antiretroviral adherence interventions: translating research findings to the real world clinic. Curr HIV/AIDS Rep. 2010;7(1):44–51. Epub 2010/04/29.PubMedCrossRefGoogle Scholar
  60. 60.
    Dieffenbach CW. Preventing HIV transmission through antiretroviral treatment-mediated virologic suppression: aspects of an emerging scientific agenda. Curr opin HIV and AIDS. 2012;7(2):106–10. Epub 2012/01/10.CrossRefGoogle Scholar
  61. 61.
    Forsyth AD, Valdiserri RO. Reaping the prevention benefits of highly active antiretroviral treatment: policy implications of HIV Prevention Trials Network 052. Curr opin HIV and AIDS. 2012;7(2):111–6. Epub 2012/01/10.CrossRefGoogle Scholar
  62. 62.
    Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399–410. Epub 2012/07/13.PubMedCrossRefGoogle Scholar
  63. 63.
    Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99. Epub 2010/11/26.PubMedCrossRefGoogle Scholar
  64. 64.
    Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367(5):423–34. Epub 2012/07/13.PubMedCrossRefGoogle Scholar
  65. 65.
    Kelesidis T, Landovitz RJ. Preexposure prophylaxis for HIV prevention. Curr HIV/AIDS Rep. 2011;8(2):94–103. Epub 2011/04/06.PubMedCrossRefGoogle Scholar
  66. 66.
    Myers GM, Mayer KH. Oral preexposure anti-HIV prophylaxis for high-risk U.S. populations: current considerations in light of new findings. AIDS Patient Care STDS. 2011;25(2):63–71. Epub 2011/02/03.PubMedCrossRefGoogle Scholar
  67. 67.
    Prevention CfDCa. Morbidity and mortality weekly report (MMWR), Interim guidance: Preexposure prophylaxis for the prevention of HIV infection in men who have sex with men. MMWR Morb mortal wkly rep. 2011;60(03):4.Google Scholar
  68. 68.
    Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367(5):411–22. Epub 2012/07/13.PubMedCrossRefGoogle Scholar
  69. 69.
    Amico KR, Liu A, McMahan V, et al. Adherence Indicators and Pre-exposure Prophylaxis (PrEP) Drug Levels in the iPrEx Study. 18th Conference on Retroviruses and Opportunistic Infections (CROI); Boston, US 2011.Google Scholar
  70. 70.
    Anderson PL, Lama J, Buchbinder S, et al. Interpreting detection rates of intracellular emtricitabine-triphosphate (FTC-TP) and tenofovir-diphosphate (TFV-DP) in the iPrEx trial. 18th Conference on Retroviruses and Opportunistic Infections (CROI); Boston, US 2011.Google Scholar
  71. 71.
    Amico KR. Adherence to preexposure chemoprophylaxis: the behavioral bridge from efficacy to effectiveness. Curr opin HIV and AIDS. 2012;7(6):542–8. Epub 2012/09/12.CrossRefGoogle Scholar
  72. 72.
    Amico KR, Liu A, Marcus JL, McMahan V, et al. Correlates of Study Product Use Among U.S. Participants in the iPrEx Randomized Controlled Trial of Daily Oral Preexposure Prophylaxis. International AIDS Conference July 2012; Washington, DC 2012.Google Scholar
  73. 73.
    Haberer J. Near perfect early adherence to antiretroviral pre-exposure prophylaxis (PrEP) against HIV infection among HIV-serodiscordant couples as determined by multiple measures: preliminary data from the Partners PrEP study. 18th Conference on Retroviruses and Opportunistic Infections; Boston, US 2011.Google Scholar
  74. 74.
    Anderson PL, Glidden DV, Liu A, Buchbinder S, Lama JR, Guanira JV, et al. Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci transl med. 2012;4(151):151ra25. Epub 2012/09/14.CrossRefGoogle Scholar
  75. 75.
    Robert M Grant FvG. HPTN 067: The ADAPT study: A Phase II, Randomized, Open-Label, Pharmacokinetic and Behavioral Study of the Use of Intermittent Oral Emtricitabine/Tenofovir Disoproxil Fumarate Pre-Exposure Prophylaxis (PrEP). 2012.Google Scholar
  76. 76.
    Roy Gulick KM, Timothy W. HPTN 069: NEXT-PREP: Novel Exploration of Therapeutics for PREP: A Phase II Randomized, Double-Blind, Study of the Safety and Tolerability of Maraviroc (MVC), Maraviroc + Emtricitabine (MVC + FTC), Maraviroc + Tenofovir disoproxil fumarate (MVC + TDF), or Tenofovir disoproxil fumarate + Emtricitabine (TDF + FTC) for Pre-Exposure Prophylaxis (PrEP) to Prevent HIV Transmission in At-Risk Men Who Have Sex with Men. 2012 Contract No.: Protocol Version 2.0.Google Scholar
  77. 77.
    Spire BMJ, Aboulker JP, Le Gall JM. Pre-exposure prophylaxis in France: IPERGAY. TasP PrEP evidence summit 2012 (International Association of Physicians in AIDS Care and British HIV Association); June 11–12 2012; London, UK 2012.Google Scholar
  78. 78.
    Administration UFaD. FDA approves first drug for reducing the risk of sexually acquired HIV infection. 2012 [cited 2012 July];
  79. 79.
    Amico KR, Mansoor LE, Corneli A, Torjesen K, Straten A van der. Adherence support approaches in biomedical HIV prevention trials: experiences, insights and future directions from four multisite prevention trials. AIDS and behavior. 2013. Epub 2013/02/26.Google Scholar
  80. 80.
    Ferrer RA, Morrow KM, Fisher WA, Fisher JD. Toward an information-motivation-behavioral skills model of microbicide adherence in clinical trials. AIDS Care. 2010;22(8):997–1005. Epub 2010/06/17.Google Scholar
  81. 81.
    Psaros C. Evaluation and Process Outcomes from an Adherence Intervention to Support HIV Pre-Exposure Prophylaxis (PrEP) Adherence in HIV-Serodiscordant Couples in Uganda. 7th Annual HIV Treatment and Prevention Adherence Conference of the International Association of Providers in AIDS Care; June 2012; Miami, FL 2012.Google Scholar
  82. 82.
    Amico KRMV, Marcus J, Goicochea P, Vargas L, Grant R, Liu A. Integrated Next Step Counseling (iNSC): A discussion based sexual health promotion conversation to support men who have sex with men using PrEP in the iPrEx open label extension. 7th Annual HIV Treatment and Prevention Adherence Conference of the International Association of Providers in AIDS Care; June, 2012; Miami, FL 2012.Google Scholar
  83. 83.
    RA K, McMahan V, Goicochea P, Vargas L, Marcus JL, Grant RM, et al. Supporting study product use and accuracy in self-report in the iPrEx study: next step counseling and neutral assessment. AIDS Behav. 2012;16(5):1243–59.CrossRefGoogle Scholar
  84. 84.
    Safren SA, Otto MW, Worth JL, Salomon E, Johnson W, Mayer K, et al. Two strategies to increase adherence to HIV antiretroviral medication: life-steps and medication monitoring. Behav Res Ther. 2001;39(10):1151–62. Epub 2001/10/03.PubMedCrossRefGoogle Scholar
  85. 85.
    Straten A van der, Van Damme L, Haberer JE, Bangsberg DR. Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention. AIDS. 2012;26(7):F13–9. Epub 2012/02/16.PubMedCrossRefGoogle Scholar
  86. 86.
    Kalichman SC, Pope H, White D, Cherry C, Amaral CM, Swetzes C, et al. Association between health literacy and HIV treatment adherence: further evidence from objectively measured medication adherence. J Int Assoc Physician AIDS Care. 2008;7(6):317–23. Epub 2008/12/06.CrossRefGoogle Scholar
  87. 87.
    Mann T, Sherman D, Updegraff J. Dispositional motivations and message framing: a test of the congruency hypothesis in college students. Health Psychol. 2004;23(3):330–4. Epub 2004/04/22.PubMedCrossRefGoogle Scholar
  88. 88.
    Ferster CB, Culbertson S. Behavior principles (3rd ed). Englewood Cliffs: Prentice-Hall; 1982.Google Scholar
  89. 89.
    Festinger L. A theory of cognitive dissonance. Stanford: Standford University Press; 1957.Google Scholar
  90. 90.
    Rogers RW. A protective motivation theory of fear appeals and attitude change. J Psychol. 1975;91:93–114.CrossRefGoogle Scholar
  91. 91.
    Rollnick S, Miller W, Butler CC. Motivational interviewing in health care: helping patients change behavior (applications of Motivational Interviewing). New York: Guilford Press; 2008.Google Scholar
  92. 92.
    Kok G, Mesters I. Getting inside the black box of health promotion programmes using intervention Mapping. Chronic illness. 2011;7(3):176–80. Epub 2011/09/09.PubMedCrossRefGoogle Scholar
  93. 93.
    Barash EA, Golden M. Awareness and use of HIV pre-exposure prophylaxis among attendees of a seattle gay pride event and sexually transmitted disease clinic. AIDS Patient Care STDS. 2010;24(11):689–91. Epub 2010/09/25.PubMedCrossRefGoogle Scholar
  94. 94.
    Brooks RA, Kaplan RL, Lieber E, Landovitz RJ, Lee SJ, Leibowitz AA. Motivators, concerns, and barriers to adoption of preexposure prophylaxis for HIV prevention among gay and bisexual men in HIV-serodiscordant male relationships. AIDS care. 2011;23(9):1136–45. Epub 2011/04/09.Google Scholar
  95. 95.
    Golub SA, Kowalczyk W, Weinberger CL, Parsons JT. Preexposure prophylaxis and predicted condom use among high-risk men who have sex with men. J Acquir Immune Defic Syndr. 2010;54(5):548–55. Epub 2010/06/01.PubMedCrossRefGoogle Scholar
  96. 96.
    Kegeles SM, Hays RB, Coates TJ. The Mpowerment Project: a community-level HIV prevention intervention for young gay men. Am J Public Health. 1996;86(8):1129–36. Epub 1996/08/01.PubMedCrossRefGoogle Scholar
  97. 97.
    Lester RT, Ritvo P, Mills EJ, Kariri A, Karanja S, Chung MH, et al. Effects of a mobile phone short message service on antiretroviral treatment adherence in Kenya (WelTel Kenya1): a randomised trial. Lancet. 2010;376(9755):1838–45. Epub 2010/11/13.PubMedCrossRefGoogle Scholar
  98. 98.
    Kop ML,K van der, Gelmon L, et al. In-depth analysis of patient-clinician cell phone communication during the WelTel Kenya1 antiretroviral adherence trial. PloS one. 2012;7(9):e46033. Epub 2012/10/11.PubMedCrossRefGoogle Scholar
  99. 99.
    Bourne C, Knight V, Guy R, Wand H, Lu H, McNulty A. Short message service reminder intervention doubles sexually transmitted infection/HIV re-testing rates among men who have 2 with men. Sex Transm Infect. 2011;87(3):229–31. Epub 2011/02/08.PubMedCrossRefGoogle Scholar
  100. 100.
    Costa TM da, Barbosa BJ, Gomes eCDA, Sigulem D, Fatima MH de, Filho AC, et al. Results of a randomized controlled trial to assess the effects of a mobile SMS-based intervention on treatment adherence in HIV/AIDS-infected Brazilian women and impressions and satisfaction with respect to incoming messages. Int J Med Inform. 2012;81(4):257–69. Epub 2012/02/03.PubMedCrossRefGoogle Scholar
  101. 101.
    Dowshen N, Kuhns LM, Johnson A, Holoyda BJ, Garofalo R. Improving adherence to antiretroviral therapy for youth living with HIV/AIDS: a pilot study using personalized, interactive, daily text message reminders. J Med Internet Res. 2012;14(2):e51. Epub 2012/04/07.PubMedCrossRefGoogle Scholar
  102. 102.
    Haberer JE, Kiwanuka J, Nansera D, Wilson IB, Bangsberg DR. Challenges in using mobile phones for collection of antiretroviral therapy adherence data in a resource-limited setting. AIDS Behav. 2010;14(6):1294–301. Epub 2010/06/10.PubMedCrossRefGoogle Scholar
  103. 103.
    Pop-Eleches C, Thirumurthy H, Habyarimana JP, Zivin JG, Goldstein MP, Walque D de, et al. Mobile phone technologies improve adherence to antiretroviral treatment in a resource-limited setting: a randomized controlled trial of text message reminders. AIDS. 2011;25(6):825–34. Epub 2011/01/22.PubMedCrossRefGoogle Scholar
  104. 104.
    Sidney K, Antony J, Rodrigues R, Arumugam K, Krishnamurthy S, D’Souza G, et al. Supporting patient adherence to antiretrovirals using mobile phone reminders: patient responses from South India. AIDS care. 2012;24(5):612–7. Epub 2011/12/14.PubMedCrossRefGoogle Scholar
  105. 105.
    Eaton LA, Kalichman S. Risk compensation in HIV prevention: implications for vaccines, microbicides, and other biomedical HIV prevention technologies. Curr HIV/AIDS Rep. 2007;4(4):165–72. Epub 2008/03/28.PubMedCrossRefGoogle Scholar
  106. 106.
    Howard AA, Arnsten JH, Lo Y, Vlahov D, Rich JD, Schuman P, et al. A prospective study of adherence and viral load in a large multi-center cohort of HIV-infected women. AIDS. 2002;16(16):2175–82. Epub 2002/11/01.PubMedCrossRefGoogle Scholar
  107. 107.
    Mannheimer S, Friedland G, Matts J, Child C, Chesney M. The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons 2 clinical trials. Clin Infect Dis. 2002;34(8):1115–21. Epub 2002/03/27.PubMedCrossRefGoogle Scholar
  108. 108.
    Cooper D. Treatment optimization in low- and middle-income countries. J Int AIDS Soc. 2012;15 Suppl 4:18080. Epub 2012/12/12.Google Scholar
  109. 109.
    Emamzadeh-Fard S, Fard SE, Seyedalinaghi SA, Paydary K. Adherence to anti-retroviral therapy and its determinants in HIV/AIDS patients: A review. Infect Disord Drug Targets. 2012;12(5):346–56. Epub 2012/09/29.PubMedCrossRefGoogle Scholar
  110. 110.
    Kalichman SC, Grebler T. Stress and poverty predictors of treatment adherence among people with low-literacy living with HIV/AIDS. Psychosom Med. 2010;72(8):810–6. Epub 2010/08/19.PubMedCrossRefGoogle Scholar
  111. 111.
    Waite KR, Paasche-Orlow M, Rintamaki LS, Davis TC, Wolf MS. Literacy, social stigma, and HIV medication adherence. J Gen Intern Med. 2008;23(9):1367–72. Epub 2008/06/20.PubMedCrossRefGoogle Scholar
  112. 112.
    Waldrop-Valverde D, Osborn CY, Rodriguez A, Rothman RL, Kumar M, Jones DL. Numeracy skills explain racial differences in HIV medication management. AIDS Behav. 2010;14(4):799–806. Epub 2009/08/12.PubMedCrossRefGoogle Scholar
  113. 113.
    Mugglin C, Estill J, Wandeler G, Bender N, Egger M, Gsponer T, et al. Loss to programme between HIV diagnosis and initiation of antiretroviral therapy in sub-Saharan Africa: systematic review and meta-analysis. Trop Med Int Health. 2012. Epub 2012/09/22.Google Scholar
  114. 114.
    MacPherson P, Corbett EL, Makombe SD, Oosterhout JJ van, Manda E, Choko AT, et al. Determinants and consequences of failure of linkage to antiretroviral therapy at primary care level in Blantyre, Malawi: a prospective cohort study. PloS one. 2012;7(9):e44794. Epub 2012/09/18.PubMedCrossRefGoogle Scholar
  115. 115.
    Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329(5996):1168–74. Epub 2010/07/21.PubMedCrossRefGoogle Scholar
  116. 116.
    Marrazzo J, Ramjee G, Nair G, Palanee T, Mkhize B, Nakabiito C, et al. Pre-exposure Prophylaxis for HIV in Women: Daily Oral Tenofovir, Oral Tenofovir/Emtricitabine, or Vaginal Tenofovir Gel in the VOICE Study (MTN 003). 20th Conference on Retroviruses and Opportunistic Infections; March 3–6, 2013; Altanta, Gorgia USA 2013.Google Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Center for Health, Intervention and PreventionUniversity of ConnecticutStorrsUSA

Personalised recommendations